MERSANA THERAPEUTICS INC's ticker is MRSN and the CUSIP is 59045L106. A total of 84 filers reported holding MERSANA THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $156,648 | -35.7% | 123,345 | +66.7% | 0.00% | – |
| Q2 2023 | $243,467 | -73.3% | 74,002 | -66.6% | 0.00% | -100.0% |
| Q1 2023 | $911,220 | +26.8% | 221,708 | +80.7% | 0.00% | 0.0% |
| Q4 2022 | $718,881 | -100.0% | 122,676 | -48.4% | 0.00% | -66.7% |
| Q3 2022 | $1,606,615,000 | -35.6% | 237,665 | -56.0% | 0.00% | -25.0% |
| Q2 2022 | $2,493,428,000 | -4.2% | 539,703 | -17.3% | 0.00% | 0.0% |
| Q1 2022 | $2,603,926,000 | -32.3% | 652,613 | +5.5% | 0.00% | -20.0% |
| Q4 2021 | $3,846,548,000 | +468.3% | 618,416 | +761.5% | 0.01% | +400.0% |
| Q3 2021 | $676,885,000 | +1893.8% | 71,780 | +2771.2% | 0.00% | – |
| Q2 2021 | $33,950,000 | -69.8% | 2,500 | -64.0% | 0.00% | – |
| Q1 2021 | $112,386,000 | -35.7% | 6,946 | +5.8% | 0.00% | – |
| Q4 2020 | $174,774,000 | -26.2% | 6,568 | -48.4% | 0.00% | – |
| Q3 2020 | $236,809,000 | +159.4% | 12,718 | +225.9% | 0.00% | – |
| Q2 2020 | $91,307,000 | +40.8% | 3,902 | -64.9% | 0.00% | – |
| Q1 2020 | $64,830,000 | +30.8% | 11,120 | +28.6% | 0.00% | – |
| Q4 2019 | $49,553,000 | +877.4% | 8,648 | +169.5% | 0.00% | – |
| Q3 2019 | $5,070,000 | -60.1% | 3,209 | +2.2% | 0.00% | – |
| Q2 2019 | $12,717,000 | -9.6% | 3,140 | +17.4% | 0.00% | – |
| Q1 2019 | $14,065,000 | +1117.7% | 2,674 | +844.9% | 0.00% | – |
| Q4 2018 | $1,155,000 | -75.6% | 283 | -40.2% | 0.00% | – |
| Q3 2018 | $4,730,000 | -44.0% | 473 | 0.0% | 0.00% | – |
| Q2 2018 | $8,448,000 | -75.4% | 473 | -78.3% | 0.00% | – |
| Q1 2018 | $34,347,000 | +96.7% | 2,178 | +104.9% | 0.00% | – |
| Q4 2017 | $17,465,000 | – | 1,063 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 1,191,271 | $6,980,848 | 6.79% |
| Bain Capital Life Sciences Investors, LLC | 8,663,673 | $50,769 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 950,000 | $5,567,000 | 3.43% |
| Sarissa Capital Management LP | 3,997,010 | $23,422,479 | 2.79% |
| Decheng Capital Management III (Cayman), LLC | 904,268 | $5,299,010 | 1.98% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,140,182 | $6,681,467 | 1.91% |
| Orbimed Advisors | 9,011,437 | $52,807,021 | 1.01% |
| Opaleye Management Inc. | 460,000 | $2,695,600 | 0.94% |
| Artal Group S.A. | 2,200,000 | $12,892 | 0.72% |
| DAFNA Capital Management LLC | 413,463 | $2,422,893 | 0.68% |